Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as TOCOSOL(R) Paclitaxel
TOCOSOL Paclitaxel · 2 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| TOCOSOL Paclitaxel | EXPERIMENTAL | TOCOSOL Paclitaxel administered weekly at 120mg/mm2 |
| Name | Type | Description |
|---|---|---|
| TOCOSOL(R) Paclitaxel | DRUG | - |
| TOCOSOL Paclitaxel | DRUG | - |
Inclusion Criteria: * Female patient with histologic diagnosis of breast carcinoma * Stage IV (M1) disease * No prior cytotoxic chemotherapy regimen for treatment of metastatic breast cancer * Adult (18 years of age or older) patients * Adequate hematologic function (ANC \>=1500 cells/mm3 and plate...
TOCOSOL Paclitaxel is an investigational small molecule oncology drug developed by Achieve Life Sciences, Inc. It has been studied in Phase 2 clinical trials for the treatment of bladder neoplasms and breast cancer. It is not approved and remains in clinical development.
TOCOSOL Paclitaxel was evaluated as initial treatment for metastatic breast cancer in a Phase 2 trial. The study enrolled 47 female patients aged 18 years and older in Russia and has been completed. The drug is investigational and has not been approved for any indication.
TOCOSOL Paclitaxel is being developed by Achieve Life Sciences, Inc., which trades under the ticker ACHV. The company is the sponsor of the clinical program for this investigational oncology asset.
TOCOSOL Paclitaxel is in Phase 2 development. It has completed Phase 2 trials in metastatic breast cancer and in transitional cell carcinoma of the urothelium. There are currently no active trials, and the drug is not FDA approved.
TOCOSOL Paclitaxel has been studied in two completed Phase 2 trials: NCT00096668 in metastatic breast cancer, which enrolled 47 patients, and NCT00077688 in metastatic or locally advanced transitional cell carcinoma of the urothelium, which enrolled 44 patients. Both trials are completed.
Yes, TOCOSOL Paclitaxel and TOCOSOL(R) Paclitaxel refer to the same investigational drug. TOCOSOL(R) is the registered trademark form of the name used in trial titles and documentation. Both names describe the same oncology asset developed by Achieve Life Sciences, Inc.